According to domestic media reports, the latest research by new york Blood Center and Virus Laboratory of Fudan University shows that a very special anti-HPV drug-anti-HPV biological protein invisible membrane can effectively prevent and treat cervical cancer caused by human papillomavirus infection.
Cervical cancer is a multiple cancer of women, mainly due to human papillomavirus (HPV) infection. Because of sexual behavior and oral sex, it is more likely to become the fuse of other cancers, such as laryngeal cancer. Early epidemiological investigation shows that 1/6 domestic women may suffer from cervical cancer, with thousands of cervical cancer patients diagnosed every year and more than thousands of deaths. Therefore, it is a long-term goal for researchers to find a drug that can effectively treat cervical cancer.
Anti-human papillomavirus biological protein stealth membrane is a kind of cell activity inhibitor of human papillomavirus, which is usually used to treat patients infected with human papillomavirus. In the latest research, the researchers found that this seemingly ordinary drug also has a certain inhibitory effect on cells infected with HIV, and has no adverse effects on healthy cells.
The head of the research team pointed out that this discovery filled the gap of anti-human papillomavirus drugs in the world. The key to the treatment of cervical cancer has always been that it cannot be found and prevented early, and the anti-HPV protein invisible membrane can kill HPV infected cells at an early stage without damaging normal cells. This early treatment is very important for patients with cervical cancer.
The results of this study lasted nearly one year, and the clinical observation items involved the negative rate of human papillomavirus, the change of human papillomavirus -DNA load, various indicators of vaginal environment, patients' self-conscious symptoms and so on. The data are accurate and reliable, and the clinical data and experimental results will be published in foreign high-level articles.
The researchers said that this research result theoretically solved the huge problem of cervical cancer treatment. Although the use of HPV vaccine has greatly reduced the incidence of cervical cancer, it has always been effective for patients infected with human papillomavirus or suffering from cervical cancer, and it is effective only when there is no human papillomavirus infection, and it generally has no effect on infected vaccines, and HPV vaccine is expensive, so researchers hope to explore more effective and cheaper treatment methods for human beings by further deepening this research and promoting anti-human papillomavirus products.
The relationship between 2.2. Human papillomavirus and cervical cancer
Human papillomavirus (HPV) exists widely in nature, and human skin, digestive tract and respiratory tract all carry HPV. Therefore, all women who have sex may be infected with human papillomavirus through sexual contact, and 70% ~ 80% of women will be infected with human papillomavirus at least once in their lives.
In China, the infection rate of high-risk human papillomavirus among urban women is15.2%; The infection rate of high-risk human papillomavirus among rural women is 14.6%, and about 60-80 million women are infected with high-risk human papillomavirus that can cause cervical cancer. It is a major gynecological disease that seriously threatens women's lives.
The World Health Organization (WHO) has confirmed that human papillomavirus infection is the primary cause of cervical cancer and a necessary condition for its occurrence. The detection rate of human papillomavirus in cervical cancer can reach 99.7%, among which HPV 16 and HPV 18 are the most common, accounting for about 70% of the incidence, which is the primary potential cause of cervical cancer.
In 2002, the global incidence of cervical cancer was 493,200, and the annual death toll was 273,500. Cervical cancer is the second most common female tumor in the world, with 78% cases occurring in developing countries. There are10.8 million new cases of cervical cancer in China every year, and the number of deaths due to cervical cancer is nearly10.8 million, which seriously endangers women's lives and health.
The E6 and E7 genes in the genome of human papillomavirus are oncogenes of the virus, and the encoded E6 and E7 proteins play a key role in virus replication. The carcinogenic effect of E6 protein is mainly through binding with P53, which inactivates P53 protein, promotes its intracellular degradation, and then destroys the detection point of cell proliferation cycle, leading to the accumulation of gene changes and the generation of malignant genotypes. At the same time, it can induce telomerase activity and make cancer cells continue to proliferate. The carcinogenic effect of E7 protein is mainly to inactivate Rb protein by binding with tumor suppressor gene Rb, which eventually leads to the continuous proliferation and development of cells infected with human papillomavirus without the control of cell cycle checkpoint.
It is a long process for human papillomavirus infection to progress to cervical cancer, so cervical cancer is a preventable and treatable malignant tumor. Cervical cancer is the only cancer that can be effectively prevented, found in time and treated early.
It is a long process for human papillomavirus infection to progress to cervical cancer, so cervical cancer is a preventable and treatable malignant tumor. Cervical cancer is the only cancer that can be effectively prevented, found in time and treated early.
Under this background, the anti-human papillomavirus biological protein dressing (invisible membrane) was developed and marketed.
Different from interferon and other commonly used anti-human papillomavirus drugs, JB protein with exclusive patent research and development can kill human papillomavirus efficiently, quickly and non-specifically, without causing virus variation, and has outstanding clinical effect, which can be used for the prevention and treatment of human papillomavirus. At the same time, it will not cause changes in the vaginal environment.
JB protein Source: Purified protein in milk. After high-tech biological treatment, the number of negative charges on its surface increased. Mechanism of JB: Based on the principle of positive and negative charge interaction, it binds to the C-terminal of L 1 region and the N-terminal of L2 region of human papillomavirus, resulting in the conformational change of human papillomavirus protein and inactivation, preventing the virus from combining with host cells, thus achieving the purpose of treating human papillomavirus infection and preventing cervical cancer.
Clinical trial is a multi-center clinical observation and global supervision in a well-known 3A teaching hospital in China. It lasted nearly a year. Clinical observation items involve the negative conversion rate of human papillomavirus, the change of human papillomavirus -DNA load, various indicators of vaginal environment, patients' self-conscious symptoms and so on. The data are accurate and reliable, and the clinical data and experimental results will be published in foreign high-level articles.
Scope of clinical application in the instruction manual
1 for the treatment of high-risk human papillomavirus infection in reproductive tract; It can be used to treat low-grade cervical lesions (CIN I) caused by high-risk human papillomavirus infection.
2. Blocking human papillomavirus infection in reproductive tract to prevent cervical precancerous lesion (CIN) and cervical cancer;
3. Improve vaginal microenvironment, reduce vaginitis reaction, reduce vaginal secretion, effectively improve vaginal cleanliness and reduce vaginal PH value.
4. Used for vaginal odor and itching caused by various types of vaginal inflammation.